Jonathan Heckart, DO
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1073004156
Payments from drug & device makers
Across 103 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$366
- Amgen$297
- Abbott$181
- Insulet Corporation$168
- Sequel Med Tech, LLC$111
- Lilly USA, LLC$97
- plus $858 from 19 others
What the payments were for
- Food & beverage$2,01897%
- Education$603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $366 |
| Amgen(2 entities) | 17 | $297 |
| Abbott | 8 | $181 |
| Insulet Corporation | 5 | $168 |
| Sequel Med Tech, LLC | 3 | $111 |
| Lilly USA, LLC | 5 | $97 |
| Johnson & Johnson | 6 | $95 |
| Medtronic | 4 | $90 |
| Boehringer Ingelheim | 5 | $89 |
| Dexcom, Inc. | 3 | $83 |
| Tandem Diabetes Care, Inc. | 3 | $77 |
| Rhythm Pharmaceuticals, Inc. | 3 | $74 |
| Corcept Therapeutics | 3 | $51 |
| AbbVie(2 entities) | 2 | $40 |
| Mannkind Corporation | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $34 |
| Bayer | 2 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Sandoz | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
How this compares
$2,078 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $161,865 |
| MounjaroTirzepatide | 64 | $72,003 |
| JardianceEmpagliflozin | 31 | $32,124 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $18,738 |
| TrulicityDulaglutide | 11 | $15,832 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $12,537 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $9,866 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $9,230 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $7,103 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $5,983 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $3,072 |
| SynthroidLevothyroxine Sodium | 42 | $2,868 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,707 |
| Novolog FlexpenInsulin Aspart | 12 | $2,113 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $366 | $161,865147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $97 | $87,83575 claims |
| Boehringer IngelheimJardiance | $89 | $32,12431 claims |
| AbbVieSynthroid | $40 | $2,86842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$7.4M
- Luis CasaubonAustin$3.5M
- Lindsay HarrisonAustin$2.2M
- Jean ChenAustin$1.8M
- Tira Chaicha-BromAustin$1.7M
- Valerie EspinosaAustin$1.2M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.